Exposure of epitope residues on the outer face of the Chikungunya virus envelope trimer determines antibody neutralizing efficacy

Journal of Virology

Volumn 88, Issue 24, 2014, Pages 14364-14379

  Fong, Rachel H ^a   Banik, Soma S R ^a   Mattia, Kimberly ^a   Barnes, Trevor ^a   Tucker, David ^a   Liss, Nathan ^b   Lu, Kai ^b   Selvarajah, Suganya ^b   Srinivasan, Surabhi ^a   Mabila, Manu ^a   Miller, Adam ^a   Muench, Marcus O ^b,c   Michault, Alain ^d   Rucker, Joseph B ^a   Paes, Cheryl ^a   Simmons, Graham ^b,c   Kahle, Kristen M ^a   Doranz, Benjamin J ^a  

^a Integral Molecular Inc   (United States)

^b BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CENTRE HOSPITALIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN E1; GLYCOPROTEIN E2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IM-CKV057; MONOCLONAL ANTIBODY IM-CKV061; MONOCLONAL ANTIBODY IM-CKV062; MONOCLONAL ANTIBODY IM-CKV063; MONOCLONAL ANTIBODY IM-CKV065; MONOCLONAL ANTIBODY IM-CKV066; MONOCLONAL ANTIBODY IM-CKV067; UNCLASSIFIED DRUG; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CHIKUNGUNYA; CHIKUNGUNYA ALPHAVIRUS; CONTROLLED STUDY; DRUG BINDING; DRUG BINDING SITE; DRUG CROSS REACTIVITY; DRUG DETERMINATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ISOLATION; DRUG RESPONSE; DRUG SCREENING; DRUG STRUCTURE; EPITOPE MAPPING; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; MOUSE; NEWBORN; NONHUMAN; PHAGE DISPLAY; PROTEIN DOMAIN; PROTEIN STRUCTURE; VIRION; VIRUS ENVELOPE; VIRUS INHIBITION; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION; ANIMAL; BINDING SITE; C57BL MOUSE; CELL SURFACE DISPLAY; CHEMICAL STRUCTURE; CHIKUNGUNYA FEVER; CHIKUNGUNYA VIRUS; DISEASE MODEL; IMMUNOLOGY; ISOLATION AND PURIFICATION; PASSIVE IMMUNIZATION; PROTEIN CONFORMATION; SURVIVAL;

CHIKUNGUNYA VIRUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BINDING SITES; CELL SURFACE DISPLAY TECHNIQUES; CHIKUNGUNYA FEVER; CHIKUNGUNYA VIRUS; DISEASE MODELS, ANIMAL; EPITOPE MAPPING; EPITOPES; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; MICE, INBRED C57BL; MODELS, MOLECULAR; PROTEIN CONFORMATION; SURVIVAL ANALYSIS; VIRAL ENVELOPE PROTEINS;

EID: 84911475829     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01943-14     Document Type: Article

References (64)

1. Robinson M. 1955. An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53. I. Clinical features. Trans. R. Soc. Trop. Med. Hyg. 49:28-32. http://dx.doi.org/10.1016/0035-9203(55)90080-8.
2. Powers AM, Logue CH. 2007. Changing patterns of Chikungunya virus: re-emergence of a zoonotic arbovirus. J. Gen. Virol. 88:2363-2377. http://dx.doi.org/10.1099/vir.0.82858-0.
3. Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S. 2007. A single mutation in Chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog. 3:e201. http://dx.doi.org/10.1371/journal.ppat.0030201.
4. Schuffenecker I, Iteman I, Michault A, Murri S, Frangeul L, Vaney MC, Lavenir R, Pardigon N, Reynes JM, Pettinelli F, Biscornet L, Diancourt L, Michel S, Duquerroy S, Guigon G, Frenkiel MP, Brehin AC, Cubito N, Despres P, Kunst F, Rey FA, Zeller H, Brisse S. 2006. Genome microevolution of Chikungunya viruses causing the Indian Ocean outbreak. PLoS Med. 3:e263. http://dx.doi.org/10.1371/journal.pmed.0030263.
5. Wu D, Zhang Y, Zhouhui Q, Kou J, Liang W, Zhang H, Monagin C, Zhang Q, Li W, Zhong H, He J, Li H, Cai S, Ke C, Lin J. 2013. Chikungunya virus with E1-A226V mutation causing two outbreaks in 2010, Guangdong, China. Virol. J. 10:174. http://dx.doi.org/10.1186/1743-422X-10-174.
6. Rezza G, Nicoletti L, Angelini R, Romi R, Finarelli AC, Panning M, Cordioli P, Fortuna C, Boros S, Magurano F, Silvi G, Angelini P, Dottori M, Ciufolini MG, Majori GC, Cassone A. 2007. Infection with Chikungunya virus in Italy: an outbreak in a temperate region. Lancet 370:1840-1846. http://dx.doi.org/10.1016/S0140-6736(07)61779-6.
7. Burt FJ, Rolph MS, Rulli NE, Mahalingam S, Heise MT. 2012. Chikungunya: a re-emerging virus. Lancet 379:662-671. http://dx.doi.org/10.1016/S0140-6736(11)60281-X.
8. de Lamballerie X, Leroy E, Charrel RN, Ttsetsarkin K, Higgs S, Gould EA. 2008. Chikungunya virus adapts to tiger mosquito via evolutionary convergence: a sign of things to come? Virol. J. 5:33. http://dx.doi.org/10.1186/1743-422X-5-33.
9. Enserink M. 2008. Entomology. A mosquito goes global. Science 320: 864-866. http://dx.doi.org/10.1126/science.320.5878.864.
10. Enserink M. 2014. Infectious diseases. Crippling virus set to conquer Western Hemisphere. Science 344:678-679. http://dx.doi.org/10.1126/science.344.6185.678.
11. Schwartz O, Albert ML. 2010. Biology and pathogenesis of Chikungunya virus. Nat. Rev. Microbiol. 8:491-500. http://dx.doi.org/10.1038/nrmicro2368.
12. Brighton SW, Prozesky OW, de la Harpe AL. 1983. Chikungunya virus infection. A retrospective study of 107 cases. S. Afr. Med. J. 63:313-315.
13. Whitby K, Pierson TC, Geiss B, Lane K, Engle M, Zhou Y, Doms RW, Diamond MS. 2005. Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J. Virol. 79:8698-8706. http://dx.doi.org/10.1128/JVI.79.14.8698-8706.2005.
14. Takhampunya R, Ubol S, Houng HS, Cameron CE, Padmanabhan R. 2006. Inhibition of dengue virus replication by mycophenolic acid and ribavirin. J. Gen. Virol. 87:1947-1952. http://dx.doi.org/10.1099/vir.0.81655-0.
15. Ying C, Colonno R, De Clercq E, Neyts J. 2007. Ribavirin and mycophenolic acid markedly potentiate the anti-hepatitis B virus activity of entecavir. Antiviral Res. 73:192-196. http://dx.doi.org/10.1016/j.antiviral.2006.10.003.
16. Akahata W, Yang ZY, Andersen H, Sun S, Holdaway HA, Kong WP, Lewis MG, Higgs S, Rossmann MG, Rao S, Nabel GJ. 2010. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat. Med. 16:334-338. http://dx.doi.org/10.1038/nm.2105.
17. Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG, Mangiafico JA. 2000. Phase II safety and immunogenicity study of live Chikungunya virus vaccine TSI-GSD-218. Am. J. Trop. Med. Hyg. 62:681-685.
18. Partidos CD, Paykel J, Weger J, Borland EM, Powers AM, Seymour R, Weaver SC, Stinchcomb DT, Osorio JE. 2012. Cross-protective immunity against O'Nyong-Nyong virus afforded by a novel recombinant Chikungunya vaccine. Vaccine 30:4638-4643. http://dx.doi.org/10.1016/j.vaccine.2012.04.099.
19. Rossi SL, Guerbois M, Gorchakov R, Plante KS, Forrester NL, Weaver SC. 2013. IRES-based Venezuelan equine encephalitis vaccine candidate elicits protective immunity in mice. Virology 437:81-88. http://dx.doi.org/10.1016/j.virol.2012.11.013.
20. Tretyakova I, Lukashevich IS, Glass P, Wang E, Weaver S, Pushko P. 2013. Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine. Vaccine 31:1019-1025. http://dx.doi.org/10.1016/j.vaccine.2012.12.050.
21. Wang D, Suhrbier A, Penn-Nicholson A, Woraratanadharm J, Gardner J, Luo M, Le TT, Anraku I, Sakalian M, Einfeld D, Dong JY. 2011. A complex adenovirus vaccine against Chikungunya virus provides complete protection against viraemia and arthritis. Vaccine 29:2803-2809. http://dx.doi.org/10.1016/j.vaccine.2011.01.108.
22. Weaver SC, Osorio JE, Livengood JA, Chen R, Stinchcomb DT. 2012. Chikungunya virus and prospects for a vaccine. Expert Rev. Vaccines 11: 1087-1101. http://dx.doi.org/10.1586/erv.12.84.
23. Gaedigk-Nitschko K, Schlesinger MJ. 1990. The Sindbis virus 6K protein can be detected in virions and is acylated with fatty acids. Virology 175: 274-281. http://dx.doi.org/10.1016/0042-6822(90)90209-A.
24. Garoff H, Wilschut J, Liljestrom P, Wahlberg JM, Bron R, Suomalainen M, Smyth J, Salminen A, Barth BU, Zhao H, Forsell K, Ekström M. 1994. Assembly and entry mechanisms of Semliki Forest virus. Arch. Virol. Suppl. 9:329-338.
25. Keranen S. 1986. Synthesis and processing of Semliki Forest virus polyprotein in Saccharomyces cerevisiae: a yeast type glycosylation of E1 envelope protein. Gene 48:267-275. http://dx.doi.org/10.1016/0378-1119(86)90085-5.
26. Lusa S, Garoff H, Liljestrom P. 1991. Fate of the 6K membrane protein of Semliki Forest virus during virus assembly. Virology 185:843-846. http://dx.doi.org/10.1016/0042-6822(91)90556-Q.
27. Ziemiecki A, Garoff H, Simons K. 1980. Formation of the Semliki Forest virus membrane glycoprotein complexes in the infected cell. J. Gen. Virol. 50:111-123. http://dx.doi.org/10.1099/0022-1317-50-1-111.
28. Voss JE, Vaney MC, Duquerroy S, Vonrhein C, Girard-Blanc C, Crublet E, Thompson A, Bricogne G, Rey FA. 2010. Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography. Nature 468:709-712. http://dx.doi.org/10.1038/nature09555.
29. Kam YW, Lee WW, Simarmata D, Harjanto S, Teng TS, Tolou H, Chow A, Lin RT, Leo YS, Renia L, Ng LF. 2012. Longitudinal analysis of the human antibody response to Chikungunya virus infection: implications for serodiagnosis and vaccine development. J. Virol. 86:13005-13015. http://dx.doi.org/10.1128/JVI.01780-12.
30. Kam YW, Lum FM, Teo TH, Lee WW, Simarmata D, Harjanto S, Chua CL, Chan YF, Wee JK, Chow A, Lin RT, Leo YS, Le Grand R, Sam IC, Tong JC, Roques P, Wiesmuller KH, Renia L, Rotzschke O, Ng LF. 2012. Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein. EMBO Mol. Med. 4:330-343. http://dx.doi.org/10.1002/emmm.201200213.
31. Warter L, Lee CY, Thiagarajan R, Grandadam M, Lebecque S, Lin RT, Bertin-Maghit S, Ng LF, Abastado JP, Despres P, Wang CI, Nardin A. 2011. Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency. J. Immunol. 186:3258-3264. http://dx.doi.org/10.4049/jimmunol.1003139.
32. Selvarajah S, Sexton NR, Kahle KM, Fong RH, Mattia KA, Gardner J, Lu K, Liss NM, Salvador B, Tucker DF, Barnes T, Mabila M, Zhou X, Rossini G, Rucker JB, Sanders DA, Suhrbier A, Sambri V, Michault A, Muench MO, Doranz BJ, Simmons G. 2013. A neutralizing monoclonal antibody targeting the acid-sensitive region in Chikungunya virus E2 protects from disease. PLoS Negl. Trop. Dis. 7:e2423. http://dx.doi.org/10.1371/journal.pntd.0002423.
33. Pal P, Dowd KA, Brien JD, Edeling MA, Gorlatov S, Johnson S, Lee I, Akahata W, Nabel GJ, Richter MK, Smit JM, Fremont DH, Pierson TC, Heise MT, Diamond MS. 2013. Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. PLoS Pathog. 9:e1003312. http://dx.doi.org/10.1371/journal.ppat.1003312.
34. Pal P, Fox JM, Hawman DW, Huang YJ, Messaoudi I, Kreklywich C, Denton M, Legasse AW, Smith PP, Johnson S, Axthelm MK, Vanlandingham DL, Streblow DN, Higgs S, Morrison TE, Diamond MS. 2014. Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes. J. Virol. 88:8213-8226. http://dx.doi.org/10.1128/JVI.01032-14.
35. Goh LY, Hobson-Peters J, Prow NA, Gardner J, Bielefeldt-Ohmann H, Pyke AT, Suhrbier A, Hall RA. 2013. Neutralizing monoclonal antibodies to the E2 protein of Chikungunya virus protects against disease in a mouse model. Clin. Immunol. 149:487-497. http://dx.doi.org/10.1016/j.clim.2013.10.004.
36. Chua CL, Chan YF, Sam IC. 2014. Characterisation of mouse monoclonal antibodies targeting linear epitopes on Chikungunya virus E2 glycoprotein. J. Virol. Methods 195:126-133. http://dx.doi.org/10.1016/j.jviromet.2013.10.015.
37. Hernandez R, Paredes A, Brown DT. 2008. Sindbis virus conformational changes induced by a neutralizing anti-E1 monoclonal antibody. J. Virol. 82:5750-5760. http://dx.doi.org/10.1128/JVI.02673-07.
38. Hunt AR, Bowen RA, Frederickson S, Maruyama T, Roehrig JT, Blair CD. 2011. Treatment of mice with human monoclonal antibody 24h after lethal aerosol challenge with virulent Venezuelan equine encephalitis virus prevents disease but not infection. Virology 414:146-152. http://dx.doi.org/10.1016/j.virol.2011.03.016.
39. Hunt AR, Frederickson S, Maruyama T, Roehrig JT, Blair CD. 2010. The first human epitope map of the alphaviral E1 and E2 proteins reveals a new E2 epitope with significant virus neutralizing activity. PLoS Negl. Trop. Dis. 4:e739. http://dx.doi.org/10.1371/journal.pntd.0000739.
40. O'Brien LM, Goodchild SA, Phillpotts RJ, Perkins SD. 2012. A humanised murine monoclonal antibody protects mice from Venezuelan equine encephalitis virus, Everglades virus and Mucambo virus when administered up to 48 h after airborne challenge. Virology 426:100-105. http://dx.doi.org/10.1016/j.virol.2012.01.038.
41. Rulker T, Voss L, Thullier P, O'Brien LM, Pelat T, Perkins SD, Langermann C, Schirrmann T, Dubel S, Marschall HJ, Hust M, Hulseweh B. 2012. Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV in vitro and in vivo. PLoS One 7:e37242. http://dx.doi.org/10.1371/journal.pone.0037242.
42. Smith TJ, Cheng RH, Olson NH, Peterson P, Chase E, Kuhn RJ, Baker TS. 1995. Putative receptor binding sites on alphaviruses as visualized by cryoelectron microscopy. Proc. Natl. Acad. Sci. U. S. A. 92:10648-10652. http://dx.doi.org/10.1073/pnas.92.23.10648.
43. Sun S, Xiang Y, Akahata W, Holdaway H, Pal P, Zhang X, Diamond MS, Nabel GJ, Rossmann MG. 2013. Structural analyses at pseudo atomic resolution of Chikungunya virus and antibodies show mechanisms of neutralization. eLife 2:e00435. http://dx.doi.org/10.7554/eLife.00435.
44. Boere WA, Benaissa-Trouw BJ, Harmsen M, Kraaijeveld CA, Snippe H. 1983. Neutralizing and non-neutralizing monoclonal antibodies to the E2 glycoprotein of Semliki Forest virus can protect mice from lethal encephalitis. J. Gen. Virol. 64(Pt 6):1405-1408. http://dx.doi.org/10.1099/0022-1317-64-6-1405.
45. Lee CY, Kam YW, Fric J, Malleret B, Koh EG, Prakash C, Huang W, Lee WW, Lin C, Lin RT, Renia L, Wang CI, Ng LF, Warter L. 2011. Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants. PLoS Pathog. 7:e1002390. http://dx.doi.org/10.1371/journal.ppat.1002390.
46. Kaur P, Chu JJ. 2013. Chikungunya virus: an update on antiviral development and challenges. Drug Discov. Today 18:969-983. http://dx.doi.org/10.1016/j.drudis.2013.05.002.
47. Lucas-Hourani M, Lupan A, Despres P, Thoret S, Pamlard O, Dubois J, Guillou C, Tangy F, Vidalain PO, Munier-Lehmann H. 2013. A phenotypic assay to identify Chikungunya virus inhibitors targeting the nonstructural protein nsP2. J. Biomol. Screen. 18:172-179. http://dx.doi.org/10.1177/1087057112460091.
48. Pohjala L, Utt A, Varjak M, Lulla A, Merits A, Ahola T, Tammela P. 2011. Inhibitors of alphavirus entry and replication identified with a stable Chikungunya replicon cell line and virus-based assays. PLoS One 6:e28923. http://dx.doi.org/10.1371/journal.pone.0028923.
49. Paes C, Ingalls J, Kampani K, Sulli C, Kakkar E, Murray M, Kotelnikov V, Greene TA, Rucker JB, Doranz BJ. 2009. Atomic-level mapping of antibody epitopes on a GPCR. J. Am. Chem. Soc. 131:6952-6954. http://dx.doi.org/10.1021/ja900186n.
50. Davidson E, Doranz BJ. 2014. A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes. Immunology 143:13-20. http://dx.doi.org/10.1111/imm.12323.
51. Salvador B, Zhou Y, Michault A, Muench MO, Simmons G. 2009. Characterization of Chikungunya pseudotyped viruses: identification of refractory cell lines and demonstration of cellular tropism differences mediated by mutations in E1 glycoprotein. Virology 393:33-41. http://dx.doi.org/10.1016/j.virol.2009.07.013.
52. Simmons G, Reeves JD, Rennekamp AJ, Amberg SM, Piefer AJ, Bates P. 2004. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc. Natl. Acad. Sci. U. S. A. 101:4240-4245. http://dx.doi.org/10.1073/pnas.0306446101.
53. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263-267. http://dx.doi.org/10.1126/science.272.5259.263.
54. Connor RI, Chen BK, Choe S, Landau NR. 1995. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206:935-944. http://dx.doi.org/10.1006/viro.1995.1016.
55. Gardner J, Anraku I, Le TT, Larcher T, Major L, Roques P, Schroder WA, Higgs S, Suhrbier A. 2010. Chikungunya virus arthritis in adult wild-type mice. J. Virol. 84:8021-8032. http://dx.doi.org/10.1128/JVI.02603-09.
56. Pierson TC, Xu Q, Nelson S, Oliphant T, Nybakken GE, Fremont DH, Diamond MS. 2007. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1:135-145. http://dx.doi.org/10.1016/j.chom.2007.03.002.
57. Couderc T, Khandoudi N, Grandadam M, Visse C, Gangneux N, Bagot S, Prost JF, Lecuit M. 2009. Prophylaxis and therapy for Chikungunya virus infection. J. Infect. Dis. 200:516-523. http://dx.doi.org/10.1086/600381.
58. Christian EA, Kahle KM, Mattia K, Puffer BA, Pfaff JM, Miller A, Paes C, Davidson E, Doranz BJ. 2013. Atomic-level functional model of dengue virus envelope protein infectivity. Proc. Natl. Acad. Sci. U. S. A. 110: 18662-18667. http://dx.doi.org/10.1073/pnas.1310962110.
59. Hammar L, Markarian S, Haag L, Lankinen H, Salmi A, Cheng RH. 2003. Prefusion rearrangements resulting in fusion Peptide exposure in Semliki Forest virus. J. Biol. Chem. 278:7189-7198. http://dx.doi.org/10.1074/jbc.M206015200.
60. Gibbons DL, Ahn A, Liao M, Hammar L, Cheng RH, Kielian M. 2004. Multistep regulation of membrane insertion of the fusion peptide of Semliki Forest virus. J. Virol. 78:3312-3318. http://dx.doi.org/10.1128/JVI.78.7.3312-3318.2004.
61. Fric J, Bertin-Maghit S, Wang CI, Nardin A, Warter L. 2013. Use of human monoclonal antibodies to treat Chikungunya virus infection. J. Infect. Dis. 207:319-322. http://dx.doi.org/10.1093/infdis/jis674.
62. Li L, Jose J, Xiang Y, Kuhn RJ, Rossmann MG. 2010. Structural changes of envelope proteins during alphavirus fusion. Nature 468:705-708. http://dx.doi.org/10.1038/nature09546.
63. Pierro DJ, Powers EL, Olson KE. 2008. Genetic determinants of Sindbis virus mosquito infection are associated with a highly conserved alphavirus and flavivirus envelope sequence. J. Virol. 82:2966-2974. http://dx.doi.org/10.1128/JVI.02060-07.
64. Mattia K, Puffer BA, Williams KL, Gonzalez R, Murray M, Sluzas E, Pagano D, Ajith S, Bower M, Berdougo E, Harris E, Doranz BJ. 2011. Dengue reporter virus particles for measuring neutralizing antibodies against each of the four dengue serotypes. PLoS One 6:e27252. http://dx.doi.org/10.1371/journal.pone.0027252.